Plant Name: Dicentra spectabilis
Taxonomic Information:
Plant ID: NPO29868
Plant Latin Name: Dicentra spectabilis
Taxonomy Genus: Dicentra
Taxonomy Family: Papaveraceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.823E-07 | 1.050E-02 | CYP2C19, CYP2D6 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.800E-05 | 1.960E-01 | CYP2C19, CYP2D6 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.175E-05 | 2.304E-01 | CYP2C19, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0019369; arachidonic acid metabolic process | 4.586E-05 | 2.497E-01 | CYP2C19, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 7.959E-05 | 2.505E-01 | CYP2C19, CYP2D6, DRD1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.592E-04 | 2.822E-01 | CYP2C19, CYP2D6 |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 3.901E-04 | 3.130E-01 | CYP2C19, CYP2D6, DRD1, LMNA |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 4.168E-04 | 3.130E-01 | CYP2C19, CYP2D6, DRD1 |
| MF | GO:0003824; catalytic activity | GO:0016705; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | 3.798E-04 | 3.130E-01 | CYP2C19, CYP2D6 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.047E-04 | 3.130E-01 | CYP2C19, CYP2D6 |
| MF | GO:0060089; molecular transducer activity | GO:0001588; dopamine neurotransmitter receptor activity, coupled via Gs | 8.281E-04 | 5.009E-01 | DRD1 |
| CC | GO:0043226; organelle | GO:0097730; non-motile cilium | 6.611E-03 | 1.000E+00 | DRD1 |
| CC | GO:0044422; organelle part | GO:0060170; ciliary membrane | 1.708E-02 | 1.000E+00 | DRD1 |
| CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 2.667E-02 | 1.000E+00 | CYP2C19, CYP2D6, DRD1, LMNA |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 7.007E-05 | 1.471E-03 | CYP2D6, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.851E-04 | 1.944E-03 | CYP2D6, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 5.788E-03 | 2.920E-02 | CYP2C19 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 9.765E-03 | 2.920E-02 | DRD1 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05031 | Amphetamine addiction | 1.333E-02 | 2.920E-02 | DRD1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.452E-02 | 2.920E-02 | CYP2D6 |
| 09160 Human Diseases | 09165 Cardiovascular diseases | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 1.472E-02 | 2.920E-02 | LMNA |
| 09160 Human Diseases | 09165 Cardiovascular diseases | hsa05410 | Hypertrophic cardiomyopathy (HCM) | 1.650E-02 | 2.920E-02 | LMNA |
| 09160 Human Diseases | 09165 Cardiovascular diseases | hsa05414 | Dilated cardiomyopathy | 1.788E-02 | 2.920E-02 | LMNA |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.630E-02 | 2.920E-02 | CYP2C19 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | DRD1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
